These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 27802078

  • 1. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
    Noh JY, Song JY, Choi WS, Lee J, Seo YB, Kwon YJ, Ko GJ, Cha DR, Kang YS, Lee YK, Cheong HJ, Kim WJ.
    Hum Vaccin Immunother; 2016 Nov; 12(11):2902-2908. PubMed ID: 27802078
    [Abstract] [Full Text] [Related]

  • 2. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ.
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [Abstract] [Full Text] [Related]

  • 3. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T, Forstén A, Arora A, Tsai T, Clemens R.
    Hum Vaccin Immunother; 2015 Sep; 11(8):2102-12. PubMed ID: 26091244
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.
    Vaccine; 2015 Jan 01; 33(1):174-81. PubMed ID: 25444803
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T, Kirstein J, Devota Go G, Leav B, Ruzycky ME, Isakov L, de Bruijn M, Oberye J, Heijnen E.
    Lancet Respir Med; 2018 May 01; 6(5):345-356. PubMed ID: 29631857
    [Abstract] [Full Text] [Related]

  • 6. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.
    Pediatr Infect Dis J; 2009 Jul 01; 28(7):563-71. PubMed ID: 19561422
    [Abstract] [Full Text] [Related]

  • 7. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
    Kumar D, Campbell P, Hoschler K, Hidalgo L, Al-Dabbagh M, Wilson L, Humar A.
    Transplantation; 2016 Mar 01; 100(3):662-9. PubMed ID: 26335915
    [Abstract] [Full Text] [Related]

  • 8. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T, Bravo L, Ceballos A, Mitha E, Gray G, Quiambao B, Patel SS, Bizjajeva S, Bock H, Nazaire-Bermal N, Forleo-Neto E, Cioppa GD, Narasimhan V.
    Vaccine; 2014 Oct 21; 32(46):6146-56. PubMed ID: 25223266
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B, Fierro C, Rosen J, Figueroa AL, Zhang B, Verhoeven C, Edelman J, Smolenov I.
    Vaccine; 2020 Jan 10; 38(2):242-250. PubMed ID: 31635976
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
    Song JY, Cheong HJ, Seo YB, Kim IS, Noh JY, Heo JY, Choi WS, Lee J, Kim WJ.
    Clin Vaccine Immunol; 2012 May 10; 19(5):638-41. PubMed ID: 22379067
    [Abstract] [Full Text] [Related]

  • 11. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.
    Vaccine; 2012 May 14; 30(23):3470-7. PubMed ID: 22446638
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients.
    Son J, Lee SB, Lee DW, Kim IY, Lee SJ, Lee SM, Song SH, Seong EY, Kwak IS.
    Clin Exp Nephrol; 2013 Apr 14; 17(2):275-83. PubMed ID: 22990301
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M, Leroux-Roels G, Rümke H, Rivera L, Pedotti P, Arora AK, Lattanzi M, Kieninger D, Cioppa GD.
    Hum Vaccin Immunother; 2015 Apr 14; 11(2):358-76. PubMed ID: 25621884
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
    Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.
    Clin Vaccine Immunol; 2011 Aug 14; 18(8):1358-64. PubMed ID: 21715575
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
    Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ.
    Clin Vaccine Immunol; 2014 Jul 14; 21(7):989-96. PubMed ID: 24828092
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.
    Pediatr Infect Dis J; 2014 Dec 14; 33(12):e320-9. PubMed ID: 24978857
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
    Solares AR, Aragon CG, Pivaral RU, Prado-Cohrs D, Sales-Carmona V, Pellegrini M, Groth N.
    J Infect Dev Ctries; 2014 Sep 12; 8(9):1160-8. PubMed ID: 25212080
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
    Song JY, Cheong HJ, Hyun HJ, Seo YB, Lee J, Wie SH, Choi MJ, Choi WS, Noh JY, Yun JW, Yun JG, Kim WJ.
    Vaccine; 2017 Jan 05; 35(2):313-320. PubMed ID: 27919632
    [Abstract] [Full Text] [Related]

  • 20. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli C, Groth N, Levin Y, Del Giudice G.
    Hum Vaccin Immunother; 2014 Jan 05; 10(6):1701-10. PubMed ID: 24732325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.